Study designs of evaluations included in the review
Randomised, double-blind controlled trials were included.
Specific interventions included in the review
Selective serotonin reuptake inhibitors (SSRIs) including: fluoxetine, paroxetine, sulpiride, fluvoxamine, mianserine, amitriptyline, citalopram, femoxetine and propranolol.
Participants included in the review
Patients with chronic pain, including headaches, diabetic neuropathy, fibromyalgia and mixed chronic pain.
Outcomes assessed in the review
The outcomes assessed were headache status, mood, pain relief, peripheral nerve function, sleep disturbance, tender point score, fatigue and depression.
How were decisions on the relevance of primary studies made?
The authors do not state how the papers were selected for the review, or how many of the authors performed the selection.